Details of the Drug
General Information of Drug (ID: DM8E9YS)
Drug Name |
Trans-dimethyl gababutin
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
ATAGABALIN; 223445-75-8; UNII-JT7957Q2FB; CHEMBL593430; JT7957Q2FB; PD-0200390; 2-[(3S,4S)-1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid; trans-dimethyl gababutin; Atagabalin [USAN:INN]; 2-((3S,4S)-1-(Aminomethyl)-3,4-dimethylcyclopentyl)acetic acid; Atagabalin (USAN/INN); SCHEMBL121610; CTK1A0230; BDBM50305887; AKOS030591721; DB12032; AN-5147; CS-0003598; PD 0200390; D09581; ((3S,4S)-1-(Aminomethyl)-3,4-dimethylcyclopentyl)acetic acid; 3,4-trans-2-(1-(aminomethyl)-3,4-dimethylcyclopentyl)acetic acid
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 185.26 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | -1.3 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||